Search

The efficacy of vitamin D supplementation in patients with systemic lupus erythematosus (SLE) remains uncertain. This meta-analysis aimed to systematically evaluate the efficacy and safety of vitamin D supplementation in patients with SLE.Randomized controlled trials (RCTs) were searched in PubMed, Embase, Cochrane CENTRAL and Web of Science databases. The retrieved studies were subjected to meta-analysis using the fixed-effect or random-effect model.Five eligible RCTs enrolling 490 participants were included. Compared to the placebo treatment, vitamin D supplementation significantly increased the level of serum 25-hydroxyvitamin D (25(OH)D) (5 trials, 490 participants: standard mean difference (SMD) = 2.072, 95% CI: 1.078-3.066, P0.001). The pooled result from 2 RCTs showed that vitamin D supplementation decreased the fatigue severity scale scores in patients with SLE (2 trials, 79 participants: SMD = -1.179, 95% CI: -1.897 to -0.460, P = 0.001). The SLE disease activity index scores and positivity of anti-double-stranded DNA antibodies (anti-dsDNA) did not differ significantly (4 trials, 223 participants: SMD = -0.507, 95% CI: -1.055-0.041, P = 0.070; 3 trials, 361 participants: Risk ratio = 0.880, 95% CI: 0.734-1.054, P = 0.165) between the vitamin D supplementation group and the placebo treatment group. None of the included studies reported severe adverse events associated with vitamin D supplementation.This meta-analysis suggested that vitamin D supplementation is effective in increasing the serum 25(OH)D levels, may improve fatigue, and is well-tolerated in patients with SLE, however, it does not seem to have significant effects in decreasing the positivity of anti-dsDNA and disease activity.

To improve the confidentiality of data transmission and the efficiency of encryption and decryption, this paper uses FPGA to improve the traditional AES encryption algorithm. The scheme uses pipeline technology to optimize the structure of AES algorithm, including the key expansion part and the encryption and decryption part. Then, the AES encryption algorithm in 128bit initial key mode is implemented, and the bit width conversion module is written, so that the encryption part can be connected with other types of bus. The experimental analysis uses Quartus tool to compile AES algorithm, and establish entity PCB circuit to test in real environment. The experimental results show that the optimization algorithm can complete the encryption and decryption function, and improve the data throughput and clock frequency.

Juvenile idiopathic arthritis (JIA) is a heterogeneous autoimmune disease characterized by arthritis of unknown etiology. JNK pathway-associated phosphatase (JKAP) is reported to be a negative regulator of T-cell activation, but its clinical role in JIA is unknown. This study aimed to investigate the correlation of JKAP with disease activity and treatment response to a tumor necrosis factor (TNF) inhibitor, etanercept (ETN), in JIA patients. Totally, 104 JIA patients (6.9 ± 2.7 years old) and 100 age- and sex-matched healthy controls (HCs) (7.2 ± 2.4 years old) were enrolled, and their serum samples were collected for measuring JKAP by enzyme-linked immunoassay. In JIA patients, after 24-week ETN treatment, clinical response was assessed based on the American College of Rheumatology pediatric criteria (ACRpedi) 50 criteria. Results showed that JKAP levels were significantly lower in JIA patients compared with HCs, and of good value in differentiating JIA patients from HCs. Among JIA patients, higher JKAP levels were associated with lower disease activity indexes, including C-reactive protein, number of joints with active arthritis, physician's global assessment of disease activity, and the present history of disease-modifying antirheumatic drugs; higher baseline JKAP levels were correlated with worse ACRpedi 50 response to ETN at week 24, and was also an independent predictive factor for worse ACRpedi 50 response to ETN. Thus, it may be inappropriate to use ETN for JIA patients with higher JKAP levels. In conclusion, serum JKAP is a potential biomarker for JIA activity and treatment response to a TNF inhibitor.

There is high uncertainty in reserve estimation during the early development of deep ultrahigh pressure gas reservoirs, largely because it remains challenging in accurately determining the formation compressibility. To overcome this, starting from the definition of compressibility, a novel gas production of cumulative unit pressure drop analysis method was established, of which the effectiveness was proven by applications in calculating the reserves of three gas reservoirs. It has been found that, in the limiting case, i.e., when the formation pressure dropped to the normal atmospheric pressure, the dimensionless gas production of the cumulative unit pressure drop was the reciprocal of the initial formation pressure. Besides, the relationship curve of the dimensionless gas production of the cumulative unit pressure drop and pressure drop was a straight line in the medium term, extending the straight line and intersecting the vertical line passing through the original formation pressure point, and the reserves can be determined according to the intersection point and the initial formation pressure. However, due to the influence of natural gas properties, the value needs further correction, and the correction coefficient depends on the pseudocritical temperature of natural gas. Specifically, when the pseudocritical temperature is given, the correction coefficient would be close to the minimum value of the natural gas deviation factor. When the pseudocritical temperature is more than 1.9 and less than 3.0, the minimum deviation factor would be between 0.90 and 1.0, and the higher the pseudocritical temperature, the closer the ratio is to 1.0.